Esperion Therapeutics (NASDAQ:ESPR) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a hold rating to a buy rating in a research report report published on Saturday.

A number of other research analysts have also recently issued reports on the stock. Needham & Company LLC raised their price target on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Piper Sandler initiated coverage on Esperion Therapeutics in a research report on Tuesday, November 25th. They issued an “overweight” rating and a $9.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Thursday, January 22nd. Citizens Jmp lifted their price target on Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “market outperform” rating in a research report on Friday. Finally, HC Wainwright reiterated a “buy” rating on shares of Esperion Therapeutics in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.60.

Esperion Therapeutics Stock Down 1.2%

ESPR opened at $2.44 on Friday. The company has a market cap of $626.62 million, a P/E ratio of -14.35, a price-to-earnings-growth ratio of 1.17 and a beta of 1.11. The firm’s 50-day moving average price is $3.28 and its 200-day moving average price is $3.14. Esperion Therapeutics has a 52-week low of $0.69 and a 52-week high of $4.18.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Tuesday, March 10th. The biopharmaceutical company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.01). The company had revenue of $168.45 million for the quarter, compared to analysts’ expectations of $165.12 million. On average, research analysts anticipate that Esperion Therapeutics will post -0.29 EPS for the current fiscal year.

Insider Transactions at Esperion Therapeutics

In other Esperion Therapeutics news, CFO Benjamin Halladay sold 7,337 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total value of $26,926.79. Following the sale, the chief financial officer directly owned 467,525 shares of the company’s stock, valued at approximately $1,715,816.75. This represents a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 15,543 shares of company stock worth $55,709 in the last three months. Insiders own 1.70% of the company’s stock.

Hedge Funds Weigh In On Esperion Therapeutics

A number of institutional investors have recently modified their holdings of the stock. R Squared Ltd boosted its stake in shares of Esperion Therapeutics by 23.5% in the fourth quarter. R Squared Ltd now owns 15,173 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 2,890 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Esperion Therapeutics by 10.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 38,955 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 3,614 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Esperion Therapeutics by 49.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,617 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 3,822 shares in the last quarter. Eaton Financial Holdings Company LLC lifted its holdings in Esperion Therapeutics by 9.4% in the fourth quarter. Eaton Financial Holdings Company LLC now owns 46,595 shares of the biopharmaceutical company’s stock valued at $172,000 after acquiring an additional 4,000 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in Esperion Therapeutics by 18.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,338 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 4,422 shares during the period. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Key Esperion Therapeutics News

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Citizens Jmp raised its price target on ESPR to $5.00 (from $4.00) and assigned a “market outperform” rating — implying roughly 105% upside vs. the reference $2.44 level, which could attract buyers and trigger short‑covering. Article Title Article Title
• Neutral Sentiment: Street analysts published Q4 forecasts for ESPR; these refreshes create short‑term volatility but are routine ahead of reporting periods — watch actual Q4 results vs. the new consensus for a catalyst. Article Title
• Negative Sentiment: HC Wainwright lowered multi‑year EPS targets materially while maintaining a “Buy” rating: FY2026 cut to $0.00 (from $0.58), FY2027 to $0.25 (from $0.81) and FY2028 to $0.45 (from $1.07). The firm also models small quarterly losses (Q1 -$0.08, Q2 -$0.05, Q3 -$0.04) before the projected recovery — the revisions reduce future earnings power embedded in current valuations and likely weigh on the stock. Article Title

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.